CCXI · Chemocentryx, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Price · CCXI
Income Statement
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Revenue | $32.22M | $64.89M | $36.13M | $11.94M | $82.50M | $11.94M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $82.99M | $77.88M | $70.28M | $62.74M | $49.49M | $37.95M |
| SG&A | $42.19M | $42.19M | $24.16M | $20.41M | $16.51M | $14.71M |
| Total Operating Expenses | $162.14M | $120.07M | $94.43M | $83.14M | $66.00M | $52.66M |
| D&A | $3.14M | $797.0K | $550.0K | $512.0K | $418.0K | $348.0K |
| Operating Income | ($129.92M) | ($55.18M) | ($58.30M) | ($40.27M) | $16.49M | ($40.72M) |
| Interest Expense | $2.69M | $2.64M | $2.15M | $1.22M | $4.0K | - |
| Income Tax | $0 | $0 | $0 | $0 | $0 | - |
| Net Income | ($131.75M) | ($55.36M) | ($55.49M) | ($37.97M) | $17.86M | ($39.96M) |
| EPS - Basic | - | - | ($0.98) | ($0.76) | ($0.86) | - |
| EPS - Diluted | - | - | ($0.98) | ($0.76) | ($0.86) | - |
Balance Sheet
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $49.98M | $32.30M | $39.18M | $28.09M | $40.02M | $12.02M |
| Accounts Receivable | - | - | $2.06M | - | $51.09M | $30.20M |
| Inventory | $0 | - | - | - | - | - |
| Accounts Payable | $6.75M | $12.88M | $1.53M | $966.0K | $1.40M | $671.0K |
| Current Assets | $269.18M | $441.57M | $174.36M | $181.38M | $179.83M | $148.69M |
| Total Assets | $425.65M | $518.90M | $209.08M | $183.31M | $189.33M | $155.87M |
| Current Liabilities | $63.02M | $51.56M | $59.08M | $64.40M | $32.94M | $38.34M |
| Long-term Debt | $4.71M | $18.10M | $19.79M | $19.69M | - | - |
| Total Liabilities | $139.53M | $133.29M | $143.08M | $168.57M | $110.06M | $105.98M |
| Stockholders' Equity | $286.12M | $385.61M | $66.00M | $14.74M | $79.27M | $49.89M |
| Retained Earnings | ($617.10M) | ($485.34M) | ($429.99M) | ($374.50M) | ($289.20M) | ($307.06M) |
Cash Flow
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($75.62M) | ($81.14M) | ($70.12M) | $39.15M | $4.88M | $39.15M |
| Investing Cash Flow | $92.22M | ($282.36M) | ($12.53M) | ($48.76M) | $15.60M | ($48.76M) |
| Financing Cash Flow | $1.08M | $356.62M | $94.82M | $8.82M | $7.52M | $8.82M |
| CapEx | $19.02M | $15.41M | $790.0K | $838.0K | $723.0K | $304.0K |
| Free Cash Flow | ($94.64M) | ($96.55M) | ($70.91M) | $38.31M | $4.16M | $38.84M |
Ratios
| Metric | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | -403.2% | -85.0% | -161.4% | -337.4% | 20.0% | -341.2% |
| EBITDA margin | -393.4% | -83.8% | -159.9% | -333.1% | 20.5% | -338.3% |
| Net margin | -408.9% | -85.3% | -153.6% | -318.1% | 21.6% | -334.8% |
| Free cash flow margin | -293.7% | -148.8% | -196.3% | 321.0% | 5.0% | 325.4% |
| FCF / Net income | 0.72 | 1.74 | 1.28 | -1.01 | 0.23 | -0.97 |
| R&D / Revenue | 257.5% | 120.0% | 194.5% | 525.6% | 60.0% | 317.9% |
| SG&A / Revenue | 130.9% | 65.0% | 66.9% | 171.0% | 20.0% | 123.3% |
| Effective tax rate | - | - | - | - | 0.0% | - |
| Return on assets | -31.0% | -10.7% | -26.5% | -20.7% | 9.4% | -25.6% |
| Return on equity | -46.0% | -14.4% | -84.1% | -257.6% | 22.5% | -80.1% |
| Return on invested capital | -35.3% | -10.8% | -53.7% | -92.4% | - | - |
| Liquidity | ||||||
| Current ratio | 4.27 | 8.56 | 2.95 | 2.82 | 5.46 | 3.88 |
| Quick ratio | 4.27 | 8.56 | 2.95 | 2.82 | 5.46 | 3.88 |
| Cash ratio | 0.79 | 0.63 | 0.66 | 0.44 | 1.22 | 0.31 |
| Leverage | ||||||
| Debt / Equity | 0.02 | 0.05 | 0.30 | 1.34 | - | - |
| Debt / Assets | 0.01 | 0.03 | 0.09 | 0.11 | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -48.2x | -20.9x | -27.1x | -32.9x | 4123.3x | - |
| Equity multiplier | 1.49 | 1.35 | 3.17 | 12.44 | 2.39 | 3.12 |
| Liabilities / Assets | 0.33 | 0.26 | 0.68 | 0.92 | 0.58 | 0.68 |
| Efficiency | ||||||
| Asset turnover | 0.08 | 0.13 | 0.17 | 0.07 | 0.44 | 0.08 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | 21d | - | 226d | 924d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -50.3% | 79.6% | 202.7% | -85.5% | 591.2% | - |
| Revenue CAGR (3y) | 39.2% | -7.7% | 44.7% | - | - | - |
| Revenue CAGR (5y) | 22.0% | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -135.5% | 5.4% | -44.8% | - | - | 14.6% |
| Net income growth (YoY) | -138.0% | 0.2% | -46.2% | - | - | 15.5% |
| EPS growth (YoY) | - | - | -28.9% | 11.6% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 2.0% | -36.2% | - | 821.9% | -89.3% | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -25.8% | 484.3% | 347.8% | -81.4% | 58.9% | -31.2% |
Stability scores
Altman Z′
FY 2021 · bankruptcy risk
-0.89
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2021 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- -Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing ChemoCentryx against the 5 most active filers in the same SIC group.